Role of hsnf5/BAF47 Loss in Human Cancer Development
Role of hsnf5/BAF47 Loss in Human Cancer Development
批准号:
8322896
负责人:
Bernard E. Weissman
金额:
$3.76万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2013-06-30
关键词:
AffectApoptosisAppearanceBindingBiochemicalBioinformaticsBiologicalBiological AssayBirthCDKN1A geneCandidate Disease GeneCell Culture TechniquesCell Cycle RegulationCell physiologyChildChromatin Remodeling FactorChromatin StructureComplexDNADNA RepairDNA SequenceDataDevelopmentDiseaseDissectionFamily memberFundingGene ExpressionGene Expression RegulationGene TargetingGenesGenetically Engineered MouseGenomic InstabilityGenomicsGerm-Line MutationGrantHealthHumanHuman DevelopmentKidneyLeadMalignant - descriptorMalignant Childhood NeoplasmMalignant NeoplasmsMating TypesModelingMolecularMusMutationNeoplastic Cell TransformationNerve TissueNeuraxisNeuronsNucleosomesPatternPlayPositioning AttributePromoter RegionsProteinsResearchRhabdoid TumorRoleSMARCB1 geneSamplingSignal PathwaySignaling Pathway GeneSpinal CordSpinal Cord NeoplasmsSucroseTechnologyTestingTranscription CoactivatorTumor Cell LineTumor Suppressor GenesTumor Suppressor ProteinsWestern Blottingbasebrain tissuecell growthchromatin modificationgene functiongenetically modified cellsinsightintegrase interactor 1manmembermouse modelneoplastic cellnervous system developmentneurodevelopmentnovelpromoterrelating to nervous systemsoft tissuetranscription factortumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The identification of tumor suppressor genes has led to new insights into the mechanisms of human cancer development. The normal functions of these genes often lie in the control of gene expression, especially in the realm of cell cycle control and cellular differentiation. Several recent studies have implicated aberrant activity of chromatin remodeling complexes in the development of human cancer. Mutations in the INI1/SNF5/BAF47 gene, a component of the SWI/SNF chromatin remodeling complex, occur in virtually all malignant rhabdoid tumors (MRTs). The SWI/SNF complex acts as a global transcriptional activator that alters nucleosome positioning on DNA via an energy-dependent mechanism. During the previous funding period, we have determined that loss of SNF5 expression affects cell cycle regulation in all MRT cell lines. We also developed 2 genetically engineered mouse (GEM) models for MRT development where loss of expression of the pRb family members or decreased expression of p53 accelerates the appearance of spinal cord MRTs. Importantly, our preliminary studies have now put forward 4 candidate genes suspected of supporting SNF5 tumor suppressor action. Based on these results, we hypothesize that loss of SNF5 expression can lead to MRT development through disruption of neural differentiation. To test this hypothesis, we propose 3 specific aims. In the first specific aim, we will characterize novel targets of SNF5 in human MRT cell lines using Taq-Man(R) assays, Western blotting and ChIPs, determine their role in MRT oncogenesis using cell culture models and assess the effects of SNF5 loss on chromatin structure and modifications in their promoter regions. The second specific aim will identify downstream targets of SNF5 associated with MRT development using a combination of high-throughput DNA sequencing approach (ChIP-seq) and gene expression array analyses. In the third specific aim, we will determine the role of Snf5 inactivation in neural cell development and malignant rhabdoid tumorigenesis using novel genetically engineered mouse models, neurosphere cultures and a comparison of mouse spinal cord MRTs with human MRTs of the central nervous system. The dissection of the role SNF5 plays in MRT development will broaden our understanding of its normal biological and biochemical activities, provide new insights into the function of the SWI/SNF complex in cell cycle regulation and normal development and identify new avenues of treatment for this highly aggressive tumor. PUBLIC HEALTH RELEVANCE: Tumor suppressor genes are turned off in many human cancers and are often responsible for the familial forms of this disease. We are studying one of these genes called INI1/SNF5/BAF47 that plays an important role in the development of an aggressive childhood cancer of the kidney, brain and soft tissues called malignant rhabdoid tumor (MRT). Our previous studies have suggested that the loss of this gene before or early after birth may interfere with normal nervous system development leading to the appearance of MRT in children. This current grant will carry out further studies to test this hypothesis using MRT cells grown in culture, DNA and protein from these cells and genetically-modified mice that will lose INI1/SNF5/BAF47 expression in nervous tissues. By doing these studies, we will broaden our understanding of its normal biological and biochemical activities and identify new avenues of treatment for this highly aggressive tumor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer Epigenetics Training Grant
-
批准号:9977976
-
项目类别:
-
资助金额:$42.6万
-
财政年份:2017
-
负责人:Bernard E. Weissman
-
依托单位:
Cancer Epigenetics Training Grant
-
批准号:9756152
-
项目类别:
-
资助金额:$37.63万
-
财政年份:2017
-
负责人:Bernard E. Weissman
-
依托单位:
Cancer Epigenetics Training Grant
-
批准号:10240322
-
项目类别:
-
资助金额:$41.39万
-
财政年份:2017
-
负责人:Bernard E. Weissman
-
依托单位:
Animal Models Core Facility
-
批准号:8340285
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2011
-
负责人:Bernard E. Weissman
-
依托单位:
SWI/SNF complex loss facilitates gene silencing during NSCLC development
-
批准号:7635080
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2009
-
负责人:Bernard E. Weissman
-
依托单位:
CORE--ANIMAL PROCEDURES
-
批准号:7100664
-
项目类别:
-
资助金额:$6.28万
-
财政年份:2004
-
负责人:Bernard E. Weissman
-
依托单位:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
-
批准号:6681590
-
项目类别:
-
资助金额:$31.22万
-
财政年份:2003
-
负责人:Bernard E. Weissman
-
依托单位:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
-
批准号:6790490
-
项目类别:
-
资助金额:$28.99万
-
财政年份:2003
-
负责人:Bernard E. Weissman
-
依托单位:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
-
批准号:7098021
-
项目类别:
-
资助金额:$28.31万
-
财政年份:2003
-
负责人:Bernard E. Weissman
-
依托单位:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
-
批准号:7267012
-
项目类别:
-
资助金额:$27.49万
-
财政年份:2003
-
负责人:Bernard E. Weissman
-
依托单位:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
-
批准号:6929953
-
项目类别:
-
资助金额:$28.99万
-
财政年份:2003
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:7278535
-
项目类别:
-
资助金额:$3.65万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:6483263
-
项目类别:
-
资助金额:$27.89万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:8287094
-
项目类别:
-
资助金额:$28.33万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
CORE--TISSUE CULTURE FACILITY
-
批准号:6563747
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:6856592
-
项目类别:
-
资助金额:$25.67万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:8396591
-
项目类别:
-
资助金额:$4.07万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:7585343
-
项目类别:
-
资助金额:$26.9万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:7486723
-
项目类别:
-
资助金额:$2.2万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
Role of hsnf5/BAF47 Loss in Human Cancer Development
-
批准号:6712798
-
项目类别:
-
资助金额:$25.67万
-
财政年份:2002
-
负责人:Bernard E. Weissman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: